We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

41 hedge funds and large institutions have $60.1M invested in Biotech Acquisition Company Unit in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

31% less funds holding

Funds holding: 59 → 41 (-18)

49% less capital invested

Capital invested by funds: $118M → $60.1M (-$58.2M)

82% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 22

Holders
41
Holders Change
-18
Holders Change %
-30.51%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
8
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
Rivernorth Capital Management
Florida
+$1.93M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$1.5M
3
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$538K
4
SMA
Sage Mountain Advisors
Georgia
+$230K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$167K

Top Sellers

Rank Fund Capital Flow
1
BCM
BlueCrest Capital Management
Jersey
-$9.89M
2
LA
Linden Advisors
New York
-$6.71M
3
PC
Periscope Capital
Ontario, Canada
-$4.91M
4
DCM
DG Capital Management
New York
-$4.45M
5
RCM
Radcliffe Capital Management
Pennsylvania
-$4.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Aristeia Capital
Connecticut
$11.6M – – –
HIM
2
HGC Investment Management
Ontario, Canada
$11.1M – – –
GCL
3
Glazer Capital LLC
New York
$7.15M -$3.46M -345,403 -33%
SRCM
4
Sage Rock Capital Management
New York
$5.78M – – –
RCM
5
Rivernorth Capital Management
Florida
$2.2M +$1.93M +193,102 +772%
ACA
6
Arena Capital Advisors
California
$2.02M – – –
CCM
7
Context Capital Management
California
$2.02M – – –
JP Morgan Chase
8
JP Morgan Chase
New York
$1.51M – – –
PMAM
9
Picton Mahoney Asset Management
Ontario, Canada
$1.51M +$1.5M +150,000 New
Millennium Management
10
Millennium Management
New York
$1.43M – – –
CIM
11
Cowen Investment Management
New York
$1.26M – – –
SCM
12
Shaolin Capital Management
Florida
$1.08M +$69K +6,888 +7%
CCFM
13
Cohen & Co Financial Management
New York
$1.01M +$1M +100,000 New
HP
14
Hound Partners
New York
$1M -$4.96K -495 -0.5%
FTCM
15
First Trust Capital Management
Illinois
$907K – – –
HF
16
HRT Financial
New York
$906K – – –
Walleye Trading
17
Walleye Trading
New York
$806K – – –
WC
18
Wealthspring Capital
New York
$611K -$15.2K -1,514 -2%
YCM
19
Yakira Capital Management
Connecticut
$542K – – –
State of Wisconsin Investment Board
20
State of Wisconsin Investment Board
Wisconsin
$542K +$538K +53,725 New
SMA
21
Sage Mountain Advisors
Georgia
$513K +$230K +22,950 +82%
WCMNY
22
Westchester Capital Management (New York)
New York
$504K – – –
BI
23
Bulldog Investors
New Jersey
$454K – – –
SSA
24
Schonfeld Strategic Advisors
New York
$449K -$501K -50,002 -53%
Janus Henderson Group
25
Janus Henderson Group
United Kingdom
$420K +$167K +16,715 +67%
1
2 3

BIOTU Hedge Fund Activity: Q2 2021 in Review

41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2021, worth a combined $60.1M — down 49% from $118M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BIOTU and 4 opened new positions — a net loss of 18 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Rivernorth Capital Management, adding an estimated $1.93M. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $9.89M sold.

  • 41 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2021, down from 59 in Q1 2021.
  • Funds reported $60.1M of Biotech Acquisition Company Unit stock for Q2 2021, down 49% quarter-over-quarter.
  • 4 funds opened new Biotech Acquisition Company Unit positions in Q2 2021 and 22 closed out, a net change of -18 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q2 2021 was Rivernorth Capital Management, an estimated $1.93M added.
  • The largest Biotech Acquisition Company Unit seller in Q2 2021 was BlueCrest Capital Management, an estimated $9.89M sold.

Based on aggregated 13F filings for Q2 2021.